Suboptimal Inhibition of Platelet Cyclooxygenase-1 by Aspirin in Metabolic Syndrome
- 1 March 2012
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Hypertension
- Vol. 59 (3), 719-725
- https://doi.org/10.1161/hypertensionaha.111.181404
Abstract
Interindividual variation in the ability of aspirin to inhibit platelet cyclooxygenase-1 (COX-1) could account for some on-treatment cardiovascular events. Here, we sought to determine whether there are clinical phenotypes that are associated with a suboptimal pharmacological effect of aspirin. In a prospective, 2-week study, we evaluated the effect of aspirin (81 mg) on platelet COX-1 in 135 patients with stable coronary artery disease by measuring serum thromboxane B2(sTxB2) as an indicator of inhibition of platelet COX-1. A nested randomized study compared enteric-coated with immediate-release formulations of aspirin. We found that sTxB2was systematically higher among the 83 patients with metabolic syndrome than among the 52 patients without (median: 4.0 versus 3.02 ng/mL;P=0.013). Twelve patients (14%) with metabolic syndrome, but none without metabolic syndrome, had sTxB2levels consistent with inadequate inhibition of COX (sTxB2≥13 ng/mL). In linear regression models, metabolic syndrome (but none of its individual components) significantly associated with higher levels of log-transformed sTxB2(P=0.006). Higher levels of sTxB2associated with greater residual platelet function measured by aggregometry-based methods. Among the randomized subset, sTxB2levels were systematically higher among patients receiving enteric-coated aspirin. Last, urinary 11-dehydro thromboxane B2did not correlate with sTxB2, suggesting that the former should not be used to quantitate aspirin's pharmacological effect on platelets. In conclusion, metabolic syndrome, which places patients at high risk for thrombotic cardiovascular events, strongly and uniquely associates with less effective inhibition of platelet COX-1 by aspirin.Keywords
This publication has 48 references indexed in Scilit:
- Pharmacodynamic Effects of Different Aspirin Dosing Regimens in Type 2 Diabetes Mellitus Patients With Coronary Artery DiseaseCirculation: Cardiovascular Interventions, 2011
- Native Platelet Aggregation and Response to Aspirin in Persons With the Metabolic Syndrome and Its ComponentsMetabolic Syndrome and Related Disorders, 2009
- Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trialsThe Lancet, 2009
- Inherited human cPLA2α deficiency is associated with impaired eicosanoid biosynthesis, small intestinal ulceration, and platelet dysfunctionJCI Insight, 2008
- Acetylation of prostaglandin H2 synthases by aspirin is inhibited by redox cycling of the peroxidaseBiochemical Pharmacology, 2008
- Aspirin “resistance” and risk of cardiovascular morbidity: systematic review and meta-analysisBMJ, 2008
- Effect of Enteric Coating on Antiplatelet Activity of Low-Dose Aspirin in Healthy VolunteersStroke, 2006
- Endothelial Microparticles and Platelet and Leukocyte Activation in Patients With the Metabolic SyndromeThe American Journal of Cardiology, 2006
- Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patientsBMJ, 2002
- Thromboxane Biosynthesis and Platelet Function in Type II Diabetes MellitusThe New England Journal of Medicine, 1990